Infective endocarditis: A review of the best treatment options

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 1899-1916

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antimicrobial chemotherapy; Enterococci; Infective endocarditis; Staphylococci; Streptococci

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFAZOLIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GARENOXACIN; GENTAMICIN; HYDROXYCHLOROQUINE; LEVOFLOXACIN; LINEZOLID; METICILLIN; METRONIDAZOLE; NAFCILLIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINUPRISTIN; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABIOTROPHIA DEFECTIVA; ACTINOBACILLUS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; BARTONELLA; CARDIOBACTERIUM; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; EIKENELLA CORRODENS; ENTEROCOCCUS; GRAM POSITIVE COCCI; HAEMOPHILUS; HEART SURGERY; HEART VALVE PROSTHESIS; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTRAVENOUS DRUG ABUSE; KINGELLA KINGAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS;

EID: 4544367466     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1899     Document Type: Review

References (125)

1. ALESTIG K, HOGEVIK H, OLAISON L: Infective endocarditis: a diagnostic and therapeutic challenge for the new millenium. Scand. J. Infect. Dis. (2000) 32:343-356.
2. MOULY S, RUIMY R, LAUNAY O et al.: The changing clinical aspects of infective endocarditis: descriptive review of 90 episodes in a French teaching hospital and risk factors for death. J. Infect. (2002) 45:246-256.
3. FERNANDEZ-GUERRERO ML, VERDEJO C, AZOFRA J, DE GORGOLAS M: Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clin. Infect. Dis. (1995) 20:16-23.
4. MYLONAKIS E, CALDERWOOD SB: Infective endocarditis in adults. N. Engl. J. Med. (2001) 345:1318-1330.
5. LE T, BAYER AS: Combination antibiotic therapy for infective endocarditis. Clin. Infect. Dis. (2003) 36:615-621.
6. KISH MA: Guide to development of practice guidelines. Clin. Infect. Dis. (2001) 32:851-854.
7. HOGEVIK H, OLAISON L, ANDERSSON R, LINDBERG J, ALESTIG K: Epidemiological aspects of infective endocarditis in an urban population-a 5-year prospective study. Medicine (Baltimore) (1995) 74:324-339.
8. STECKELBERG JM, MELTON LJ 3rd, ILSTRUP DM, ROUSE MS, WILSON WR: Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am. J. Med. (1990) 88:582-588.
9. WATANAKUNAKORN C, BURKERT T: Infective endocarditis at a large community teaching hospital, 1980-1990: a review of 210 episodes. Medicine (Baltimore) (1993) 72:90-102.
10. STROM BL, ABRUTYN E, BERLIN JA et al.: Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation (2000) 102:2842-2848.
11. FRONTERA JA, GRADON JD: Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. Clin. Infect. Dis. (2000) 30:374-379.
12. MANOFF SB, VLAHOV D, HERSKOWITZ A et al.: Human immunodeficiency virus infection and infective endocarditis among injecting drug users. Epidemiology (1996) 7:566-570.
13. ZUPPIROLI A, RINALDI M, KRAMER-FOX R, FAVILLI S, ROMAN MJ, DEVEREUX RB: Natural history of mitral valve prolapse. Am. J. Cardiol. (1995) 75:1028-1032.
14. VLESSIS AA, HOVAGUIMIAM H, JAGGERS J, AHMAD A, STARR A: Infective endocarditis: ten-year review of medical and surgical therapy. Ann. Thorac. Surg. (1996) 61:1217-1222.
15. ARVAY A, LENGYEL M: Incidence and risk factors of prosthetic valve endocarditis. Eur. J. Cardiothorac. Surg. (1988) 2:340-346.
16. CALDERWOOD SB, SWINSKI LA, WATERNAUX CM, KARCHMER AW, BUCKLEY MJ: Risk factors for the development of prosthetic valve endocarditis. Circulation (1985) 72:31-37.
17. PATEL R, PIPER KE, ROUSE MS, UHL JR, COCKERILL FR 3rd, BECKELBERG JM: Frequency of isolation of Staphylococcus lungdunensis among staphylococcal isolates causing endocarditis: a 20-year experience. J. Clin. Microbiol. (2000) 38:4262-4263.
18. GOUELLO JP, ASFAR P, BRENET O, KOUATCHET A, BERTHELOT G, ALQUIER P: Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. Crit. Care. Med. (2000) 28:377-382.
19. FANG G, KEYS TF, GENTRY LO et al.: Prosthetic valve endocarditis resulting from nosocomial bacteremia: a prospective, multicenter study. Ann. Intern. Med. (1993) 119:560-567.
20. HEIRO M, NIKOSKELAINEN J, ENGBLOM E, KOTILAINEN E, MARTTILA R, KOTILAINEN P: Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in England. Arch. Intern. Med. (2000) 160:2781-2787.
21. STECKELBERG JM, MURPHY JG, BALLARD D et al: Emboli in infective endocarditis: the prognostic value of echocardiography. Ann. Intern. Med. (1991) 114:635-640.
22. PASCHALIS C, PUGSLEY W, JOHN R, HARRISON MJ: Rate of cerebral embolic events in relation to antibiotic and anticoagulant therapy in patients with bacterial endocarditis. Eur. Neurol. (1990) 30:87-89.
23. HECHT SR, BERGER M: Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann. Intern. Med. (1992) 117:560-566.
24. RENZULLI A, CAROZZA A, MARRA C et al.: Are blood and valve cultures predictive for long-term outcome following surgery for infective endocarditis? Eur. J. Cardiothorac. Surg. (2000) 17:228-233.
25. VON REYN CF, LEVY BS, ARBEIT RD, FRIEDLAND G, CRUMPACKER CS: Infective endocarditis: an analysis based on strict case definitions. Ann. Intern. Med. (1981) 94:505-518.
26. DURACK DT, LUKES AS, BRIGHT DK: New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am. J. Med. (1994) 96:200-209.
27. LI JS, SEXTON DJ, MICK N et al.: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin. Infect. Dis. (2000) 30:633-638.
28. SEKERES MA, ABRUTYN E, BERLIN JA et al.: An assessment of the usefulness of the Duke criteria for diagnosing active infective endocarditis. Clin. Infect. Dis. (1997) 24:1185-1190.
29. BAYER AS: Revised diagnostic criteria for infective endocarditis. Cardiol. Clin. (1996) 14:345-350.
30. PEREZ-VAZQUEZ A, FARINAS MC, GARCIA-PALOMO JD, BERNAL JM, REVUELTA JM, GONZALEZ-MACIAS J: Evaluation of the Duke criteria in 93 episodes of prosthetic valve endocarditis: could sensitivity be improved? Arch. Intern. Med. (2000) 160:1185-1191.
31. DODDS GA, SEXTON DJ, DURACK DT, BASHORE TM, COREY GR, KISSLO J: Negative predictive value of the Duke criteria for infective endocarditis. Am. J. Cardiol. (1996) 77:403-407.
32. WERNER GS, SCHULZ R, FUCHS JB et al.: Infective endocarditis in the elderly in the era of transesophageal echocardiography: clinical features and prognosis compared with younger patients. Am. J. Med. (1996) 100:90-97.
33. DANIEL WG, MUGGE A, GROTE J et al.: Comparison of transthoracic and transesophageal echocardiography for detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am. J. Cardiol. (1993) 71:210-215.
34. HOEN B, SELTON-SUTY C, LACASSIN F et al.: Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin. Infect. Dis. (1995) 20:501-506.
35. GOLDENBERGER D, KUNZLI A, VOGT P, ZBINDEN R, ALTWEGG M: Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing. J. Clin. Microbiol. (1997) 35:2733-2739.
36. Working Party of the British Society for Antimicrobial Chemotherapy: Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis. Heart (1998) 79:207-210.
37. WILSON WR, KARCHMER AW, DAJANI AS et al.: Antibiotic treatment of adults with infective endocarditis due to streptococci, enterocooci, staphylococci, and HACEK microorganisms. JAMA (1995) 274:1706-1713.
38. HORSTKOTTE D, FOLLATH F, GUTSCHIK E et al.: Guidelines on prevention, diagnosis and treatment of infective endocarditis. Executive summary. Eur. Heart J. (2004) 25:267-276.
39. FRANCIOLI P, RUCH W, STAMBOULIAN D: Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin. Infect. Dis. (1995) 21:1406-1410.
40. ELIOPOULOS GM: Aminoglycoside resistant enterococcal endocarditis. Infect. Dis. North. Am. (1993) 7:117-133.
41. ELIOPOULOS GM, ELIOPOULOS CT: Therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:118-126.
42. RODER BL, WANDALL DA, ESPERSEN F, FRIMODT-MOLLER N, SKINHOJ P, ROSDAHL VT: Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am. J. Med. (1997) 102:379-386.
43. DELAHAYE F, CELARD M, ROTH O, DE GEVIGNEY G: Indications and optimal timing for surgery in infective endocarditis. Heart (2004) 90:618-620.
44. GRIFFIN FM Jr, JONES G, COBBS CC: Aortic insufficiency in bacterial endocarditis. Ann. Intern. Med. (1972) 76:23-28.
45. MILLIS J, UTLEY J, ABBOTT J: Heart failure in infective endocarditis: predisposing factors, course, and treatment. Chest (1974) 66:151-157.
46. REINHARTZ O, HERRMANN M, REDLING F, ZERKOWSKI HR: Timing of surgery in patients with acute infective endocarditis. J. Cardiovasc. Surg. (Torino) (1996) 37:397-400.
47. DELAHAJE F, GOULET V, LACASSIN F et al.: Characteristics of infective endocarditis in France 1991: a one-year survey. Eur. Heart J. (1995) 16:394-401.
48. ARANKI SF, SANTINI F, ADAMS DH et al.: Aortic valve endocarditis. Determinants of early survival and late morbidity. Circulation (1994) 90:II175-II182.
49. ELLIS ME, AL-ABDELY H, SANDRIDGE A, GREER W, VENTURA W: Fungal endocarditis: evidence in the world literature, 1965-1995. Clin. Infect. Dis. (2001) 32:50-62.
50. JAULT F, GANDJBAKHCH I, RAMA A et al.: Active native valve endocarditis: determination of operative death and late mortality. Ann. Thorac. Surg. (1997) 63:1737-1741.
51. MATSUSHITA K, KURIYAMA Y, SAWADA T et al.: Hemorragic and ischemic cerebrovascular complications of active infective endocarditis of native valve. Eur. Neurol. (1993) 33:267-274.
52. DRINKOVIC D, MORRIS AJ, POTTUMARTHY S, MACCULLOCH D, WEST T: Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J. Antimicrob. Chemother. (2003) 52:820-825.
53. JOHN MD, HIBBERD PL, KARCHMER AW, SLEEPER LA, CALDERWOOD SB: Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin. Infect. Dis. (1998) 26:1302-1309.
54. KORZENIOWSKI O, SANDE MA: Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann. Intern. Med. (1982) 97:496-503.
55. MORRIS AJ, DRINKOVIC D, POTTUMARTHY S et al.: Gram stain, culture and histopathological examination findings for heart valves removed because of infective endocarditis. Clin. Infect. Dis. (2003) 36:697-704.
56. WATANAKUNAKORN C, BAIRD IM: Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am. J. Med. Sci. (1977) 273:133-139.
57. ABRAMS B, SKLAVER A, HOFFMAN T, GREENMAN R: Single or combination therapy of staphylococcal endocarditis inintravenous drug abusers. Ann. Intern. Med. (1979) 90:789-791.
58. DWORKIN RJ, LEE BL, SANDE MA, CHAMBERS HF: Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet (1989) 2(8671):1071-1073.
59. CHAMBERS HF, MILLER RT, NEWMAN MD: Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann. Intern. Med. (1988) 109:619-624.
60. CHANG FY, PEACOCK JE, MUSHER DM et al.: Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) (2003) 82:333-339.
61. HELDMAN AW, HARTERT TV, RAY SC et al.: Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. (1996) 101:68-76.
62. HAMBURGER M, STEIN L: Streptococcus viridans subacute bacterial endocarditis: two week treatment schedule with penicillin. JAMA (1952) 149:542-545.
63. KARCHMER AW, MOELLERING RC, MAKI DG, SWARTZ MN: Single-antibiotic therapy for streptococcal endocarditis. JAMA (1979) 241:1801-1806.
64. CHUARD C, HERRMANN M, VAUDAUX P et al.: Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. (1991) 35:2611-2616.
65. LUCET JC, HERRMANN M, ROHNER P et al.: Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (1990) 34:2312-2317.
66. SIMON GL, SMITH RH, SANDE MA: Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases. Rev. Infect. Dis. (1983) 5(Suppl. 3):S507-S508.
67. ETIENNE J, EYKYN SJ: Increase in native valve endocarditis caused by coagulase-negative staphylococci: an Anglo-French clinical and microbiological study. Br. Heart J. (1990) 64:381-384.
68. PLOY MC, GRELAUD C, MARTIN C, DE LUMBLEY L, DENIS F: First clinical isolate of vancomycin-intermediate Staphylococcus auleus in a French hospital. Lancet (1998) 351:1212.
69. SMITH T, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin-resistance in Staphylococcus aureus. N. Engl. J. Med. (1999) 340:493-501.
70. BOUANCHAUD DH: In vitro and in vivo synergistic activity and fractional inhibitory concentration of the components of a semi-synthetic streptogramin, RP 59500. J. Antimicrob. Chemother. (1992) 30:95-99.
71. FANTIN B, LECLERQ R, MERLE Y et al.: Critical influence of resistance to streptogramin B type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. (1995) 39:400-405.
72. PAVIE J, LEFORT A, ZARROUK V et al.: Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics. Antimicrob. Agents Chemother. (2002) 46:3061-3064.
73. BATARD E, JACQUELINE C, BOUTOILLE D et al.: Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob. Agents Chemother. (2002) 46:2174-2178.
74. BIRMINGHAM MC, CRAIG RR, HAFKIN B et al: Critical care patients with significant, resistant, Gram-positive infections enrolled in the linezolid compassionate use protocol. Crit. Care Med. (1999) 27(Suppl. 12):S42.
75. CHIEN JW, KUCIA ML, SALATA RA: Use of linezolid, an oxazolidinone in the treatment of multidrug-resistant Gram-positive bacterial infections. Clin. Infect. Dis. (2000) 30:146-151.
76. DAILEY C, DILETO-FANG CL, BUCHANAN LV et al.: Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2001) 45:2304-2308.
77. CHAMBERS HF, LIU QX, CHOW LL, HACKBARTH C: Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob. Agents Chemother. (1999) 43:2742-2746.
78. ENTENZA JM, VOUILLAMOZ J, GLAUSER MP, MOREILLON P: Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci. Antimicrob. Agents Chemother. (2004) 48:86-92.
79. RUIZ ME, GUERRERO IC, TUAZON CU: Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin. Infect. Dis. (2002) 35:1018-1020.
80. CHIANG FY, CLIMO M: Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47:3002-3004.
81. HUEBNER J, GOLDMANN DA: Coagulase-negative staphylococci: role as pathogens. Ann. Rev. Med. (1999) 50:223-236.
82. ARBER N, MILITIANU A, BEN-YEHUDA A et al.: Native valve Staphylococcus epidermidis endocarditis: report of seven cases and review of the literature. Am. J. Med. (1991) 90:758-762.
83. SHUTTLEWORTH R, COLBY WD: Staphylococcus lungdunensis endocarditis. J. Clin. Microbiol. (1992) 30:1948-1952.
84. KARCHMER AW, ARCHER GL, DISMUKES WE: Staphylococcus epidermidis prosthetic valve endocarditis: microbiological and clinical observations as guide to therapy. Ann. Intern. Med. (1983) 98:447-455.
85. SCHWALBE RS, STAPELTON JT, GILLIGAN PH: Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. (1987) 316:927-931.
86. YU VL, ZURAVLEFF JJ, BORNHOLM J, ARCHER G: In-vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis. J. Antimicrob. Chemother. (1984) 14:359-366.
87. MILLER MH, EL-SOKKARY MA, FEINSTEIN SA, LOWY FD: Penicillin-induced effects on streptomycin uptake and early bactericidal activity differ in viridans group and enterococcal streptococci. Antimicrob. Agents Chemother. (1986) 30:763-768.
88. RAVINDRAN V, JOHN J, KAYE GC, MEIGH RE: Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J. Infect. (2003) 47:164-166.
89. MOUTON JW, ENDTZ HP, DEN HOLLANDER JG, VAN DEN BRAAK N, VERBRUGH HA: In-vitro activity of quinupristin-dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J. Antimicrob. Chemother. (1997) 39(Suppl. A):75-80.
90. LEFORT A, LORTHOLARY O, CASASSUS P et al.: Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch. Intern. Med. (2002) 162:2450-2456.
91. SAMBOLA A, MIRO JM, TORNOS MP et al.: Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin. Infect. Dis. (2003) 34:1576-1584.
92. SCULLY BF, SPRIGGS D, NEU HC: Streptococcus agalactiae (group B) endocarditis: a description of twelve cases and review of the literature. Infection (1987) 15:169-176.
93. BETRIU C, GOMEZ M, SANCHEZ A, CRUCEYRA A, ROMERO I, PICAZO J: Antibiotic resistance and penicillin tolerance in clinical isolates of group B streptococci. Antimicrob. Agents Chemother. (1994) 38:2183-2186.
94. BACKES RJ, ROUSE MS, HENRY NK, GERASI J, WILSON W: Activity of penicillin combined with an aminoglycoside against group B streptococci in vitro and in experimental endocarditis. J. Antimicrob. Chemother. (1986) 18:491-498.
95. WILSON WR: Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and other streptococci. The Endocarditis Working Group of the International Society for Chemotherapy. Clin. Microbiol. Infect. (1998) 4(Suppl. 3):S17-S26.
96. LEVY CS, KOGULAN P. GILL VJ, CROXTON MB, KANE JG, LUCEY DR: Endocarditis caused by penicillin-resistant viridans streptococci: 2 cases and controversies in therapy. Clin. Infect. Dis. (2001) 33:577-579.
97. OLAISON L, SCHADEWITZ K: Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin. Infect. Dis. (2002) 34:159-166.
98. HODGES TL, ZIGHELBOIM-DAUM S, ELIOPOULOS GM et al.: Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob. Agents Chemother. (1992) 36:121-125.
99. HUSNI R, RAAD IM: Treatment and prevention of vancomycin-resistant enterococcus. Curr. Opin. Infect. Dis. (1997) 10:431-434.
100. MOELLERING RC Jr, WENNERSTEN C, WEINSTEIN AJ: Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob. Agents Chemother. (1973) 3:526-529.
101. MATSUMOTO JY, WILSON WR, WRIGHT AJ, GERACI JE, WASHINGTON JA 2nd: Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob. Agents Chemother. (1980) 18:944-947.
102. MAINARDI JL, GUTMANN L, ACAR JF, GOLDSTEIN FW: Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob. Agents Chemother. (1995) 39:1984-1987.
103. THOMPSON RL, LAVIN B, TALBOT GH: Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin-dalfopristin and high-dose ampicillin. South Med. J. (2003) 96:818-820.
104. PATEL R, ROUSE MS, PIPER KE, STECKELBERG JM: Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob. Agents Chemother. (2001) 45:621-623.
105. BABCOCK HM, RITCHIE DJ, CHRISTIANSEN E, STARLIN R, LITTLE R, STANLEY S: Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin. Infect. Dis. (2001) 32:1373-1375.
106. RAO N, WHITE GJ: Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin. Infect. Dis. (2002) 35:902-904.
107. ZIMMER SM, CALIENDO AM, THIGPEN MC, SOMANI J: Failure of linezolid treatment for enterococcal endocarditis. Clin. Infect. Dis. (2003) 37:e29-e30.
108. BROUQUI P, RAOULT D: Endocarditis due to rare and fastidious bacteria. Clin. Microbiol. Rev. (2001) 14:177-207.
109. FERNANDEZ-GUERRERO ML: Zoonotic endocarditis. Infect. Dis. Clin. North Am. (1993) 7:135-152.
110. FOURNIER PE, LELIEVRE H, EYKYN SJ et al.: Epidemiologic and clinical characteristics of Bartonella quintana and Bartonella henselae endocarditis: a study of 48 patients. Medicine (Baltimore) (2001) 80:245-251.
111. TOMPKINS LS, ROESSLER BJ, REDD SC, MARKOWITZ LE, COHEN ML: Legionella prosthetic-valve endocarditis. N. Engl. J. Med. (1988) 318:530-535.
112. GREENE JN, SANDIN RL, VILLANUEVA L, SINNOTT JT: Haemophilus parainfluenzae endocarditis in a patient with mitral valve prolapse. Ann. Clin. Lab. Sci. (1993) 23:203-206.
113. COHEN JI, SLOSS LJ, KUNDSIN R, GOLIGHTLY L: Prosthetic-valve endocarditis caused by Mycoplasma hominis. Am. J. Med. (1989) 86:819-821.
114. POPAT K, BARNARDO D, WEBB-PEPLOE M: Mycoplasma pneumoniae endocarditis. Br. Heart J. (1980) 44:111-112.
115. RAOULT D, HOUPIKIAN P, TISSOT DUPONT H, RISS JM, ARDITI-DIJANE J, BROUQUI P: Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. (1999) 159:167-173.
116. ROLAIN JM, MALLET MN, RAOULT D: Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis. J. Infect. Dis. (2003) 188:1322-1325.
117. HENRY NK, WILSON WR, ROBERTS RB, ACAR JF, GERACI JE: Antimicrobial therapy of experimental endocarditis caused by nutritionally variant viridans group streptococci. Antimicrob. Agents Chemother. (1986) 30:465-467.
118. HOEN B: Special issues in the management of infective endocarditis caused by Gram-positive cocci. Infect. Dis. Clin. North Am. (2002) 16:437-452.
119. SHAPIRO DS, KENNEY SC, JOHNSON M, DAVIS CH, KNIGHT ST, WYRICK PB: Brief report: Chlamydia psittaci endocarditis diagnosed by blood culture. N. Engl. J. Med. (1992) 326:1192-1195.
120. MOREILLON P, QUE YA: Infective endocarditis. Lancet (2004) 363:139-149.
121. DURACK DT: Prevention of infective endocarditis. N. Engl. J. Med. (1995) 332:38-44.
122. LACASSIN F, HOEN B, LEPORT C et al.: Procedures associated with infective endocarditis in adults : a case control study. Eur. Heart J. (1995) 16:1968-1974.
123. VAN DER MEER JT, WIJK WV, THOMPSON J et al.: Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet (1992) 339:135-139.
124. STROM BL, ABRUTYN E, BERLIN JA et al.: Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann. Intern. Med. (1998) 129:761-769.
125. DAJANI AS, TAUBERT KA, WILSON W et al.: Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin. Infect. Dis. (1997) 25:1448-1458.